DE69716914D1 - Behandlung und prophylaxe von unerwünschten effekten reaktiver sauerstoffverbindungen - Google Patents

Behandlung und prophylaxe von unerwünschten effekten reaktiver sauerstoffverbindungen

Info

Publication number
DE69716914D1
DE69716914D1 DE69716914T DE69716914T DE69716914D1 DE 69716914 D1 DE69716914 D1 DE 69716914D1 DE 69716914 T DE69716914 T DE 69716914T DE 69716914 T DE69716914 T DE 69716914T DE 69716914 D1 DE69716914 D1 DE 69716914D1
Authority
DE
Germany
Prior art keywords
reactive oxygen
prophylaxis
treatment
oxygen species
oxygen compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69716914T
Other languages
English (en)
Other versions
DE69716914T2 (de
Inventor
D Horwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
University of Colorado
Original Assignee
University of Colorado Boulder
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder, University of Colorado filed Critical University of Colorado Boulder
Publication of DE69716914D1 publication Critical patent/DE69716914D1/de
Application granted granted Critical
Publication of DE69716914T2 publication Critical patent/DE69716914T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
DE69716914T 1996-02-09 1997-02-07 Behandlung und prophylaxe von unerwünschten effekten reaktiver sauerstoffverbindungen Expired - Lifetime DE69716914T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/598,926 US5670545A (en) 1996-02-09 1996-02-09 Method for the treatment of ischemic disease and reperfusion injury and the prevention of the adverse effects of reactive oxygen species
PCT/US1997/002024 WO1997028792A1 (en) 1996-02-09 1997-02-07 Traitement and prevention of adverse effects of reactive oxygen species

Publications (2)

Publication Number Publication Date
DE69716914D1 true DE69716914D1 (de) 2002-12-12
DE69716914T2 DE69716914T2 (de) 2003-07-03

Family

ID=24397503

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69716914T Expired - Lifetime DE69716914T2 (de) 1996-02-09 1997-02-07 Behandlung und prophylaxe von unerwünschten effekten reaktiver sauerstoffverbindungen

Country Status (13)

Country Link
US (2) US5670545A (de)
EP (1) EP0910355B1 (de)
JP (1) JP2001500104A (de)
CN (1) CN1097457C (de)
AT (1) ATE227125T1 (de)
AU (1) AU713754B2 (de)
CA (1) CA2246236C (de)
CZ (1) CZ291763B6 (de)
DE (1) DE69716914T2 (de)
EA (2) EA001800B1 (de)
ES (1) ES2185909T3 (de)
HU (1) HUP9901969A3 (de)
WO (1) WO1997028792A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391899B1 (en) * 1998-07-17 2002-05-21 North Shore—Long Island Jewish Research Institute Compounds and compositions for treating tissue ischemia
EP1475434A1 (de) 2003-05-09 2004-11-10 Oncoscience AG Verfahren zur Lagerung von Tumorzellen
US8735154B2 (en) 2006-10-30 2014-05-27 The University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
US20090263780A1 (en) * 2008-04-17 2009-10-22 Yanming Wang Organ preservation fluid
WO2010014953A1 (en) * 2008-08-01 2010-02-04 The Regents Of The University Of Colorado, A Body Corporate Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling
WO2013016544A2 (en) 2011-07-27 2013-01-31 University Of Kansas Templated islet cells and small islet cell clusters for diabetes treatment
WO2023184031A1 (en) * 2022-03-30 2023-10-05 Revive Therapeutics Ltd Method and use of bucillamine in the prevention and treatment of stroke

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51148090A (en) * 1975-06-12 1976-12-18 Santen Pharmaceut Co Ltd Process for stabilizing an aqueous lysozyme solution
JPS535112A (en) * 1976-03-08 1978-01-18 Santen Pharmaceutical Co Ltd New cysteine derivatives
US4053651A (en) * 1976-05-10 1977-10-11 E. R. Squibb & Sons, Inc. Compounds and method for alleviating angiotensin related hypertension
JPS545916A (en) * 1977-06-17 1979-01-17 Santen Pharmaceutical Co Ltd Novel cystein derivative
JPS5912119B2 (ja) * 1977-10-29 1984-03-21 参天製薬株式会社 アミノ酸誘導体の製造方法
JPS6058908B2 (ja) * 1978-10-11 1985-12-23 参天製薬株式会社 システイン誘導体
JPS5551021A (en) * 1978-10-11 1980-04-14 Santen Pharmaceut Co Ltd Remedy for hepatic disorder
JPS6011888B2 (ja) * 1978-10-11 1985-03-28 参天製薬株式会社 リウマチ疾患治療薬
JPS5756454A (en) * 1980-09-20 1982-04-05 Santen Pharmaceut Co Ltd Disulfide type cysteine derivative
US5292926A (en) * 1988-01-25 1994-03-08 Santen Pharmaceutical Co., Ltd. Cysteine derivatives
JPH04154714A (ja) * 1990-10-17 1992-05-27 Shiseido Co Ltd 毛髪還元剤及び毛髪化粧料
JP2816500B2 (ja) * 1990-10-17 1998-10-27 参天製薬株式会社 抗骨粗鬆剤
JP3066608B2 (ja) * 1991-01-16 2000-07-17 参天製薬株式会社 腎疾患治療剤
JP2814033B2 (ja) * 1992-01-10 1998-10-22 参天製薬株式会社 シスチン尿症治療剤
JP2843955B2 (ja) * 1992-08-01 1999-01-06 参天製薬株式会社 抗白内障剤
JP2899740B2 (ja) * 1994-02-08 1999-06-02 参天製薬株式会社 炎症性腸疾患治療剤

Also Published As

Publication number Publication date
CN1097457C (zh) 2003-01-01
EP0910355B1 (de) 2002-11-06
US5756547A (en) 1998-05-26
EA199800665A1 (ru) 1999-08-26
DE69716914T2 (de) 2003-07-03
CA2246236A1 (en) 1997-08-14
AU713754B2 (en) 1999-12-09
ATE227125T1 (de) 2002-11-15
HUP9901969A2 (hu) 1999-11-29
EA200000762A1 (ru) 2001-04-23
EP0910355A4 (de) 1999-04-28
EA001800B1 (ru) 2001-08-27
CN1210461A (zh) 1999-03-10
ES2185909T3 (es) 2003-05-01
JP2001500104A (ja) 2001-01-09
AU2264497A (en) 1997-08-28
US5670545A (en) 1997-09-23
CZ246998A3 (cs) 1998-11-11
HUP9901969A3 (en) 2001-08-28
EP0910355A1 (de) 1999-04-28
CZ291763B6 (cs) 2003-05-14
CA2246236C (en) 2006-12-19
WO1997028792A1 (en) 1997-08-14

Similar Documents

Publication Publication Date Title
BR0214772A (pt) sistemas e métodos para o tratamento de pacientes com células lipoaspiradas processadas
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
DE68915834D1 (de) Herstellung von T-Zellen und T-Zellmembranen, verwendbar zur Verhütung und Behandlung von Autoimmunkrankheiten.
ATE259644T1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
FI922325A0 (fi) Oral sammansaettning foer botning av inflammatoriska tarmkanalsjukdomar.
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69932414D1 (de) Indole-3-propionsäure, ihre salze und ester als arzneimittel
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69716914D1 (de) Behandlung und prophylaxe von unerwünschten effekten reaktiver sauerstoffverbindungen
NO994330L (no) Metode for behandling av en tumor
TR199802501T2 (xx) Yara sarg�s�.
ATE233483T1 (de) Wässrige lösung zum konservieren von gewebe und organen
DK0661987T3 (da) Morphogeninduceret leverregeneration
NO20020829D0 (no) Ny anvendelse av docetaxel for behandling av hepatoma
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE60330888D1 (de) Verwendung von drospirenon zur behandlung von hypertension
HUP9901188A2 (hu) Új, meghatározott enzimkeverékek sejtkinyeréshez és sebkezeléshez
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
EA200600402A1 (ru) Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови
ATE555787T1 (de) Behandlungseffekte von überschüssigen reaktiven sauerstoffspezies
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE335080T1 (de) Rekombinante proteine abgeleitet von hgf und msp
ATE437635T1 (de) Medium zur radikalen therapie von tumoren, von entzündungsprozessen, von pilzinfektionen und von anderen affektionen der geweben; diagnostische und prophylaktische verfahren sowie deren implementierung

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: VONNEMANN, KLOIBER & KOLLEGEN, 80796 MUENCHEN

8364 No opposition during term of opposition